Donavan Cheng serves as the Chief Science and Technology Officer at Ambry Genetics since May 2022, overseeing a 200-person organization that integrates Informatics and R&D, and driving product and technology initiatives under Tempus AI. Prior roles include VP of Informatics at Ambry Genetics, where significant bioinformatics modernization achievements led to the launch of several innovative genomic assays, and Sr. Director of Bioinformatics at Guardant Health, focusing on the Guardant Reveal assay. Cheng's experience also encompasses senior positions at Illumina, Memorial Sloan-Kettering Cancer Center, and Hoffmann-La Roche, contributing to diverse projects in bioinformatics, software development, and molecular diagnostics. Cheng holds a PhD in Biomedical Engineering from The Johns Hopkins University School of Medicine and a Bachelor of Applied Science in Engineering Science/Biomedical Engineering from the University of Toronto.
This person is not in any teams
This person is not in any offices